Zura Bio Limited
NASDAQ:ZURA · NASDAQ Capital Market
+$0.07 today
Vol 1.27M · Avg 0.75M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ZURA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$75.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.09, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $42.1M +72.5% | $24.4M -44.5% | $44.0M +85.7% | $23.7M | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $33.2M +7.7% | $30.8M +65.2% | $18.6M +436.7% | $3.5M +218.0% | $1.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $75.2M +36.3% | $55.2M -11.9% | $62.6M +130.6% | $27.2M +2387.4% | $1.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $49.0K +444.4% | $9.0K | $0 | $0 | $0 | $374.2M | $1.2B | $631.8M |
| EBITDA | -$68.6M -30.9% | -$52.4M +13.5% | -$60.6M -121.6% | -$27.3M -424.7% | $8.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$75.2M -36.3% | -$55.2M +11.9% | -$62.6M -130.6% | -$27.2M -2387.4% | -$1.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.3M -20.8% | $8.0M +265.9% | $2.2M +383408.8% | $570 -97.6% | $23.5K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.6M +136.8% | $2.8M +34.3% | $2.1M +1313.5% | -$171.0K -101.8% | $9.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$68.7M -31.0% | -$52.4M +13.5% | -$60.6M -121.6% | -$27.3M -424.7% | $8.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$68.7M -31.0% | -$52.4M +13.2% | -$60.4M -134.5% | -$25.7M -405.8% | $8.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -76.7% | -$1 +71.3% | -$2 -1095.2% | $0 -47.5% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -76.7% | -$1 +71.3% | -$2 -1095.2% | $0 -47.5% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $94.2M +25.4% | $75.1M +127.0% | $33.1M +91.7% | $17.3M +0.0% | $17.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $94.2M +25.4% | $75.1M +127.0% | $33.1M +91.7% | $17.3M +0.0% | $17.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$387.23M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$290.79M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$280.21M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$243.37M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$216.67M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$212.75M
Immuneering Corporation
NASDAQ:IMRX
$157.73M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$127.66M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$116.96M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.63M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ZURA generate?
Zura Bio Limited (ZURA) reported $0.00 of revenue in fiscal 2025.
Is ZURA profitable?
Zura Bio Limited (ZURA) reported -$68,650,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.